Abilify

Otsuka and Proteus' drug adherence device

FDA device rebuff thwarts Abilify's adherence boost

Back in September, Otsuka and partner Proteus Digital Health submitted an application to the FDA for their new drug adherence device. The agency reviewed the submission and, underwhelmed by what it found, said that it needs more information before it gives its final stamp of approval.